CURIS INC
S-1, EX-27.3, 2000-11-29
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: CURIS INC, S-1, EX-27.1, 2000-11-29
Next: CURIS INC, S-1, EX-27.4, 2000-11-29


WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
REPROGENESIS, INC. AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>                     <C>
<PERIOD-TYPE>                   6-MOS                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000             DEC-31-1999
<PERIOD-START>                             JAN-01-2000             JAN-01-1999
<PERIOD-END>                               JUN-30-2000             JUN-30-1999
<CASH>                                       2,561,562                       0
<SECURITIES>                                         0                       0
<RECEIVABLES>                                  418,315                       0
<ALLOWANCES>                                         0                       0
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                             3,167,808                       0
<PP&E>                                       2,324,103                       0
<DEPRECIATION>                               (827,916)                       0
<TOTAL-ASSETS>                               4,722,005                       0
<CURRENT-LIABILITIES>                        2,226,579                       0
<BONDS>                                        674,969                       0
                                0                       0
                                     74,318                       0
<COMMON>                                       183,722                       0
<OTHER-SE>                                   1,562,417                       0
<TOTAL-LIABILITY-AND-EQUITY>                 1,820,457                       0
<SALES>                                              0                       0
<TOTAL-REVENUES>                               434,423               2,072,448
<CGS>                                        7,523,300               4,509,123
<TOTAL-COSTS>                                7,523,300               4,509,123
<OTHER-EXPENSES>                                     0                       0
<LOSS-PROVISION>                                     0                       0
<INTEREST-EXPENSE>                              76,797                 929,708
<INCOME-PRETAX>                            (7,063,322)             (2,091,859)
<INCOME-TAX>                                         0                       0
<INCOME-CONTINUING>                        (7,063,322)             (2,091,859)
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                               (7,063,322)             (2,091,859)
<EPS-BASIC>                                     (1.45)                  (0.19)
<EPS-DILUTED>                                   (1.45)                  (0.19)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission